Proteon Therapeutics, Inc. (NASDAQ:PRTO) reached 118.18% versus a 1-year low price of $1.10. The stock was last seen 26.32% higher, reaching at $2.4 on 01/11/2018. At recent session, the prices were hovering between $1.9 and $2.55. This company shares are -10.42% up from its target price of $2.15 and the current market capitalization stands at $41.18M. The recent change has given its price a 28.62% lead over SMA 50 and -12.73% deficit over its 52-week high. The stock witnessed 29.73% gains, 5.51% gains and 65.52% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found PRTO’s volatility during a week at 8.84% and during a month it has been found around 5.11%.Proteon Therapeutics, Inc. (PRTO) Top Holders
Institutional investors currently hold around $17 million or 72.3% in PRTO stock. Look at its top three institutional owners. Abingworth Llp owns $3.83 million in Proteon Therapeutics, Inc., which represents roughly 9.31% of the company’s market cap and approximately 22.55% of the institutional ownership. Similar statistics are true for the second largest owner, Pharmstandard International S.A., which owns 1,667,907 shares of the stock are valued at $3.17 million. The third largest holder is Ra Capital Management, Llc, which currently holds $2.54 million worth of this stock and that ownership represents nearly 6.17% of its market capitalization.Proteon Therapeutics, Inc. 13F Filings
At the end of 09/30/2017 reporting period, 7 institutional holders increased their position in Proteon Therapeutics, Inc. (NASDAQ:PRTO) by some 584,731 shares, 10 decreased positions by 75,412 and 13 held positions by 8,153,194. That puts total institutional holdings at 8,813,337 shares, according to SEC filings. The stock grabbed 2 new institutional investments totaling 24,864 shares while 4 institutional investors sold out their entire positions totaling 51,624 shares.Proteon Therapeutics, Inc. (NASDAQ:PRTO) Insider Trades
Multiple company employees have indulged in significant insider trading. Proteon Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that SVP and Chief Medical Officer Burke Steven Keith has acquired 12,000 shares of Proteon Therapeutics, Inc. (PRTO) in trading session dated Dec. 15, 2017. These shares are worth $22,560 and were traded at $1.88 each. The SEC filing shows that Flynn James E performed a sale of 110,557 shares. The disposed these shares by way of transaction on Nov. 30, 2017. The company’s shares were given away at $1.75 per share worth to an income of some $193,475 on account of Flynn James E.
, Flynn James E, purchased 110,557 common shares of Proteon Therapeutics, Inc. (PRTO) in the open market. In a transaction dated Nov. 30, 2017, the shares were bought at an average price of $1.75, giving away a sum of $193,475. After this purchase, 1,224,899 common shares of PRTO are directly owned by the insider, with total stake valued at $2,939,758.
In the transaction dated Nov. 14, 2017, the great number of shares acquired came courtesy the Sr VP, CFO, Treasr, Asst Secy; Eldridge, George Arthur added a total of 295 shares at an average price of $1.69, amounting to approximately $499. The insider now directly owns 14,295 shares worth $34,308.Proteon Therapeutics, Inc. (PRTO) Analyst Guide
Several analysts have released their opinion on Proteon Therapeutics, Inc. (NASDAQ:PRTO), with 0 analysts believing it is a strong buy. Whereas 5 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 3 average brokerage recommendation.